Diagnosed cases of B-cell non-Hodgkin’s lymphoma (NHL) are set to increase by 15% in the next decade, according to a new analysis.
Analysts GlobalData say the complexity of the disease mean health services need a “nuanced” understanding of its sub-types.
They studied prevalence of the disease in seven wealthy countries: the USA, UK, Japan, France, Germany, Italy and Spain. The researchers say the number of annual diagnoses in these seven countries will increase from 200,844 in 2023 to 229,804 in 2033.
The number of patients living with the disease five years or more will increase from 634,000 to 714,000.
Senior epidemiologist Zachary Natale said: “Despite the progress that has been made, B-cell NHL remains a complex spectrum of malignant neoplasms, each of which exhibits idiosyncratic clinical manifestations and behaviours.
“Due to its heterogenous impact on the clinical course of patients, it is imperative for healthcare workers, public health professionals, and researchers to develop a more nuanced understanding of B-cell NHL’s subtypes to best address them as respective diseases.”
Source: GlobalData
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News.